P/E ratio for Trinity Biotech (TRIB)
P/E ratio as of March 2025 (TTM): -0.8554
According to Trinity Biotech 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.855446. At the end of 2022 the company had a P/E ratio of -3.86.
P/E ratio history for Trinity Biotech from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.86 | -102.29% |
| 2021 | 169 | -369.46% |
| 2020 | -62.6 | 1586.44% |
| 2019 | -3.71 | -65.74% |
| 2018 | -10.8 | -18.82% |
| 2017 | -13.3 | 70.5% |
| 2016 | -7.83 | -112.46% |
| 2015 | 62.8 | -45.75% |
| 2014 | 116 | -59.28% |
| 2013 | 284 | 226.99% |
| 2012 | 87.0 | 26.31% |
| 2011 | 68.9 | 344.26% |
| 2010 | 15.5 | -57.03% |
| 2009 | 36.1 | -1573.52% |
| 2008 | -2.45 | -90.55% |
| 2007 | -25.9 | -112.33% |
| 2006 | 210 | 202.72% |
| 2005 | 69.4 | 86.22% |
| 2004 | 37.3 | -31.46% |
| 2003 | 54.4 | 286.59% |
| 2002 | 14.1 | -77.06% |
| 2001 | 61.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | 5.96 | -796.35% | 🇺🇸 USA |
 | -45.9 | 5,260.35% | 🇺🇸 USA |
 | 46.1 | -5,488.28% | 🇺🇸 USA |
 | -0.3792 | -55.68% | 🇺🇸 USA |
 | 202 | -23,719.26% | 🇺🇸 USA |
 | 34.6 | -4,145.09% | 🇺🇸 USA |
 | 26.8 | -3,229.64% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.